Incretin-Based Drugs Market 2017 – 2027 | AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG
Incretins are a group of metabolic hormones that stimulate on the decrease in blood glucose levels. Incretin-based drugs include dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like peptide-1 receptor agonists, which are a relatively new group of drugs used in the treatment of type 2 diabetes. These drugs are associated with a low risk of hypoglycemia and have the favorable effect on body weight. Oral anti-diabetic drugs fail to maintain the desired normal levels of glucose, particularly during postprandial conditions, this has resulted in a strong need for better therapeutics like incretin-based drugs. Incretin-based drugs increase the secretion of insulin by acting on pancreatic beta cells and also inhibits the release of glucagon by acting on the pancreatic alpha cells. Incretin-based drugs namely Incretin mimetics (GLP-1 agonist) and DPP-4 inhibitors work on the antidiabetic principle of incretin hormone.Incretin-Based Drugs Market: Drivers and Restraints
The major drivers of global incretin-based drugs market are the sedentary lifestyle, rising old age population, increasing rate of cardiovascular diseases, obesity, increasing incidence of diabetes, and raising awareness of diabetes. Also, a large number of pre-diagnosed and undiagnosed patients across the globe are further fuel the market growth for incretin-based drugs. But the lack of reimbursement, poor accessibility to drugs especially in developing countries, high safety concerns and high treatment cost associated with incretin-based drugs are likely some of the restraints of incretin-based drugs market.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4528
Incretin-Based Drugs Market: Segmentation
By drug type, the incretin-based drugs market can be segmented into,
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
By formulation, the incretin-based drugs market can be segmented into,
Oral Drugs
Injectable Drugs
By distribution channel, the incretin-based drugs market can be segmented into,
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Several large cohorts of patients with diabetes, the use of incretin-based drugs as compared with combinations of oral antidiabetic drugs were not associated with an increased risk of hospitalization for heart failure.
Incretin-Based Drugs Market: Overview
Approximately 26 million diabetic patients in the United States and 35 million in the European Union alone is growing prevalence of diabetes worldwide posing a major public health challenge. Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are committed to ensuring the safety of drug products marketed for the treatment of diabetes and post marketing reports of pancreatitis and pancreatic cancer in patients taking certain antidiabetic medications like incretin-based drugs. Working in parallel, these agencies have reviewed epidemiologic data, clinical trial data and nonclinical toxicology studies related to blood glucose lowering drug products like exenatide and sitagliptin which are incretin-based drugs that stimulate postprandial insulin release by potentiating the incretin hormone pathways. The results highlighted that these incretin-based drugs reduce body weight and have better cardiovascular outcomes.
Incretin-Based Drugs Market: Region-wise Outlook
Regionally, the market can be segmented into North America, Eastern Europe, Western Europe, Asia-Pacific excluding Japan, Japan, Latin America and the Middle East and Africa. Global demand for incretin-based drugs is anticipated to be influenced by favorable government policies. Governments in many countries are taking steps to subsidize diabetes drugs so that economically weaker sections of the society have access to quality healthcare. Technological innovation in the development of drugs is also expected to provide an impetus to the growth of the market. Availability of rapid acting and long acting insulin analogs is emerging as an effective way of managing both Type 1 and Type 2 diabetes. Demand for incretin-based drugs is increasing in Asia-Pacific, whereas North America and Western Europe are lucrative markets for incretin-based drugs owing to increasing awareness on diabetes diagnosis and management.
Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-4528
Incretin-Based Drugs Market: Key Players
Some of the major market players of incretin-based drugs market include AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd and Sanofi S.A. New product launches and approvals are a few strategies adopted by top industry players. In March 2015, Takeda Pharmaceutical got Japanese approval for oral tablet Zarate, a DPP-4 inhibitor. Recently GlaxoSmithKline launched subcutaneous injection of Tanzeum (albiglutide), a GLP-1 agonist for the treatment of type 2 diabetes.
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.
U.S. Office, 616 Corporate Way, Suite 2-9018,, Valley Cottage, NY 10989,, United States, T: +1-347-9
616 Corporate Way, Suite 2-9018,
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Incretin-Based Drugs Market 2017 – 2027 | AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG here
News-ID: 1530763 • Views: …
More Releases from future market insights.
Facial Implants Market 2018 - 2028 | Key Players Include Implatech Associates In …
Facial implants are a type of medical device used to correct the facial structure or to provide more defined facial features including cheeks or chin & jawline. Facial Implants products are used for cosmetic reasons & are also used in medical crises such as accidents and injuries. Facial implants are also designed for augmentative or reconstructive surgeries. Facial implants give long lasting and permanent results that are a key factor…
Pericarditis Treatment Market 2018 - 2028 | Pfizer Inc., Bayer AG, PerkinElmer I …
Global Pericarditis Treatment: Market Insights
Pericarditis is a cardiovascular disease which represents the swelling of the pericardium wall of the heart. The main cause of pericardium disease is the inflammation of pericardium wall which is generally caused by viral infection. Other causes of pericarditis disease are renal failure, bacterial infections and intake of some drugs such as procainamide.
Some of the common symptoms of pericarditis disease are shortness of breath, fatigue, rapid…
Aldosteronism Treatment Market Drivers and Restraints | 2018 - 2028 Key Players …
Aldosteronism is a type of hormonal disorder that occurs due to an imbalance in aldosterone and further leads to high blood pressure. In Aldosteronism, aldosterone is produced in excess by the adrenal gland that exceeds the normal body requirement. This causes the sodium levels to increase and lowers the potassium levels in the body. High levels of sodium in the blood lead to a high volume of blood and ultimately…
Contouring Implants Market 2018 - 2028 | Key Players are ALPHA-HEALTH (ASIA) PTE …
Body Contouring refers to the medical-surgical procedure that alternates the shape of parts of the body via the removal of fat or skin. Body contouring implants procedures includes reshaping and resizing certain areas so the persons overall appearance is more balanced and in proportion. Body contouring implants are foreign materials that is made and molded prior to the person’s surgery and then inserted into the appropriate site. The body contouring…
More Releases for Incretin
Incretin Based Drugs Market Top Leading Players with Strategies and Forecast 202 …
The global incretin-based drugs market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2022-2028). Increased research activity, government initiatives to promote disease awareness, and research grants are primary factors which are expected to fuel the global incretin-based drug market's growth over the forecast period. Furthermore, rising government spending in R&D activities, as well as new product releases by numerous prominent companies, are expected to…
Incretin-Based Drugs Market to acquire new heights with increase in innovations
Global Incretin-Based Drugs Market research report provides a detailed market overview along with the analysis of cost structure, supply chain, development management techniques, financial support, retailer analysis, business strategies, and marketing channels. The Global Incretin-Based Drugs Market research report presents a key analysis of the market structure of the leading manufacturers with the best facts and figures, definition, meaning, SWOT analysis, latest development techniques across the world. Not only this…
Incretin-based Drugs Market to Witness an Outstanding Growth by 2025
Incretins are metabolic hormones that are activated when blood glucose levels decrease in the body. Incretin-based drugs are used in the treatment of type 2 diabetes. These drugs are associated with low risk of hypoglycemia and deliver positive effect on body weight. Oral anti-diabetic drugs often fail to maintain the desired glucose levels postprandial. This has increased demand for better and highly efficient therapeutics such as incretin-based drugs.
Incretin-based drugs assist…
Incretin-based Drugs Market Size, Status and Forecast up to 2025
Incretins are metabolic hormones that are activated when blood glucose levels decrease in the body. Incretin-based drugs are used in the treatment of type 2 diabetes. These drugs are associated with low risk of hypoglycemia and deliver positive effect on body weight. Oral anti-diabetic drugs often fail to maintain the desired glucose levels postprandial. This has increased demand for better and highly efficient therapeutics such as incretin-based drugs.
View Report -
https://www.transparencymarketresearch.com/incretinbased-drugs-market.html
Incretin-based…
Incretin based Drugs Market Insights and Analysis for Period 2017 - 2025
Incretins are metabolic hormones that are activated when blood glucose levels decrease in the body. Incretin-based drugs are used in the treatment of type 2 diabetes. These drugs are associated with low risk of hypoglycemia and deliver positive effect on body weight. Oral anti-diabetic drugs often fail to maintain the desired glucose levels postprandial. This has increased demand for better and highly efficient therapeutics such as incretin-based drugs. Incretin-based drugs…
Incretin-Based Drugs Market Forecast and Opportunity Assessment by Future Market …
Incretins are a group of metabolic hormones that stimulate on the decrease in blood glucose levels. Incretin-based drugs include dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like peptide-1 receptor agonists, which are a relatively new group of drugs used in the treatment of type 2 diabetes. These drugs are associated with a low risk of hypoglycemia and have the favorable effect on body weight. Oral anti-diabetic drugs fail to maintain the desired…